Sign up to SCR Digest, our FREE weekly newsletter, and receive our Notes emailed directly to you.
Email Address *
First Name
Mailing Lists *

MNOV: Raises $40 Million in Underwritten Public Offering

By David Bautz, PhD


Financial Update

On February 12, 2018, MediciNova (NASDAQ:MNOV) announced the closing of an underwritten public offering of approximately 4.4 million shares of its common stock at a price of $9.05 per share, which resulted in gross proceeds to the company of approximately $40 million. The company also granted the underwriters a 30-day option to purchase up to an additional 662,983 shares at the public offering price less underwriting discounts.

On February 13, 2018, MediciNova filed form 10-K with financial results for the fourth quarter and full year 2017. As expected, the company did not record any revenues for either the fourth quarter or full year 2017. Net loss for 2017 was $11.2 million, or $0.32 per share, which included $4.2 million in R&D expenses, $8.8 million in G&A expenses, and a $1.7 million deferred income tax benefit due to the Tax Cuts and Jobs Act of 2017. Operating cash burn for 2017 was approximately $6.9 million, which was much lower than the operating loss due to approximately $4.5 million in non-cash stock-based compensation.

MediciNova exited 2017 with approximately $28.0 million in cash and cash equivalents and following the recent financing we believe the company will exit the first quarter of 2018 with approximately $63 million in cash and cash equivalents.

Data Presentations Upcoming in April 2018

MediciNova, Inc. (NASDAQ:MNOV) will have data presented on two of its lead compounds in April 2018:

1) Final data and future directions for the Phase 2 clinical trial of MN-166 (ibudilast) in patients with amyotrophic lateral sclerosis (ALS) will be presented at the American Academy of Neurology (AAN) 70th Annual Meeting on April 27, 2018. The company recently announced positive top-line results from that study, which showed the primary endpoint of the study (safety and tolerability) was achieved and there were efficacy trends in key functional secondary endpoints that favored MN-166. Please see our previous report for analysis of the results. 

2) An interim analysis of the ongoing Phase 2 clinical trial of MN-001 (tipelukast) in patients with nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) will be presented at the 53rd annual meeting of the European Association for the Study of the Liver (EASL) on April 13, 2018. Tipelukast is an orally available small molecule that has anti-fibrotic and anti-inflammatory effects as a leukotriene receptor antagonist, a PDE inhibitor, and 5-lipoxygenase inhibitor. The Phase 2 trial is a multi-center, proof-of-concept, open-label study consisting of men and women age 21 to 65 with a histologically confirmed diagnosis of NASH or imaging study confirmed NAFLD and elevated serum triglyerides. Patients are receiving 250 mg MN-001 once a day for four weeks followed by 250 mg MN-001 twice a day for an additional eight weeks. The primary endpoints of the study are to evaluate the effect of MN-001 on triglyceride levels and cholesterol efflux in NASH or NAFLD patients with hypertriglyceridemia. Secondary endpoints include safety and tolerability along with the effect of MN-001 on lipid levels, liver enzymes, and percent fat in the liver at Week 12. 


Following the recent financing, MediciNova is now well funded to initiate a Phase 3 trial in progressive MS while also being in a strong financial position to maintain leverage during potential partnership negotiations. We anticipate the company will meet with the FDA later in the year to get guidance on a Phase 3 trial for MN-166 in progressive MS, however we believe it will be similar to the Phase 3 trial for Ocrevus® and enroll approximately 700 patients in total. The trial could commence as quickly as the second half of 2018. Following the release of the progressive MS data from the Phase 2b SPRINT-MS trial earlier in the month (see our analysis here) we raised our fair value estimate from $13 to $18 and we believe investors should take a close look at MediciNova as the company prepares to launch a Phase 3 program in progressive MS.


SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. 

DISCLOSURE: Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer HERE.
User ID:
Remember my ID: